-
Voretigene neparvovec, sold
under the
brand name Luxturna, is a gene
therapy medication for the
treatment of
Leber congenital amaurosis. Leber's congenital...
- the U.S. Food and Drug
Administration approved Luxturna (voretigene
neparvovec-rzyl) for the
treatment of
patients with
viable retinal cells and confirmed...
- 2019 film
directed by
Gaspar Noé Luxturna,
trade name for
voretigene neparvovec, a gene
therapy for the
treatment of Leber's
congenital amaurosis Sanctuary...
-
tiparvovec (2012),
Strimvelis (2016),
tisagenlecleucel (2017),
voretigene neparvovec (2017),
patisiran (2018),
onasemnogene abeparvovec (2019), idecabtagene...
-
vorasidenib (INN)
Voraxaze voreloxin (USAN, INN)
voretigene neparvovec (USAN, INN)
voretigene neparvovec-rzyl
voriconazole (INN)
vorinostat (USAN)
vorozole (INN)...
- RPE65
Subretinal I–II
Multiple Several ongoing and
complete (voretigene
neparvovec) Age-related
macular degeneration sFlt-1
Subretinal I–II 24
Ongoing Duchenne...
- for wet age-related
macular degeneration (AMD).
Luxturna (voretigene
neparvovec), for Leber's
congenital amaurosis.
MabThera (rituximab), for B-cell chronic...
-
December 2017, the U.S. Food and Drug
Administration approved voretigene neparvovec-rzyl (Luxturna), an adeno-****ociated
virus vector-based gene
therapy for...
- The
first retinal gene
therapy to be
approved by the FDA was
Voretigene neparvovec in 2017,
which treats Leber's
congenital amaurosis, a
genetic disorder...
-
black and white. In 2017 the FDA
approved the gene
therapy voretigene neparvovec to
treat people with
biallelic RPE65 mutation-****ociated
retinal dystrophy...
